Highlights

  • 100th commercial WiSE cardiac implant achieved in Q2 2026, a key symbolic milestone for the US launch
  • CMS initiates National Coverage Determination process for WiSE, advancing the reimbursement pathway
  • Q2 2026 preliminary revenue of US$2.50M–US$2.60M; Q1 2026 revenue of US$2.4M / A$3.4M
  • TGA Priority Review Determination received in Australia, accelerating local regulatory review

EBR Systems Inc (ASX:EBR), trading at A$0.24 as at 30 October 2026, has passed a pivotal commercialisation milestone in the United States after achieving its 100th commercial implant of the WiSE Cardiac Resynchronisation Therapy System – the world's only wireless cardiac pacing device for heart failure – while advancing on two fronts critical to long-term commercial success: reimbursement certainty through the US Centers for Medicare & Medicaid Services and regulatory approval in Australia.

100th Commercial WiSE Implant and US Commercial Momentum

EBR Systems announced in August 2026 that it had achieved the 100th commercial WiSE implant milestone in the United States, representing cumulative commercial and clinical study procedures performed since FDA approval. The milestone was preceded by 46 WiSE commercial implants completed in Q2 2026 alone, with 17 new purchasing contracts signed across hospital networks and implanting centres during the quarter. Q2 2026 preliminary revenue was reported in the range of US$2.50 million to US$2.60 million. This followed Q1 2026 revenue of US$2.4 million (approximately A$3.4 million), during which case volumes more than doubled compared with Q4 2025, representing the fastest quarterly growth since commercial launch. EBR's management noted the Company's commercial strategy had shifted focus toward deepening utilisation within already-activated accounts, rather than simply expanding the number of sites.

CMS National Coverage Determination – A Reimbursement Game Changer

The single most significant development for EBR's long-term commercial outlook in 2026 has been the initiation of a National Coverage Determination (NCD) process for the WiSE System by the Centers for Medicare & Medicaid Services. An NCD effectively creates a national reimbursement policy for Medicare beneficiaries across all states, replacing the current patchwork of local coverage policies and removing the reimbursement uncertainty that is among the most common barriers to hospital adoption of new medical devices. CMS receiving an NCD request and formally initiating the review process signals that EBR has satisfied preliminary clinical and coverage criteria to be considered for a nationwide determination. A positive NCD could dramatically accelerate hospital adoption by removing administrative reimbursement friction for each individual implanting centre and payer.

TGA Priority Review in Australia

Subsequent to the close of Q1 2026, EBR received a Priority Review Determination from the Australian Therapeutic Goods Administration (TGA) for the WiSE CRT System. This designation allows for an accelerated regulatory review timeline toward inclusion on the Australian Register of Therapeutic Goods (ARTG). EBR has indicated it intends to submit its ARTG inclusion application in the near term. The TGA priority designation is particularly meaningful given the growing evidence base for WiSE in complex CRT patient populations who have limited cardiac resynchronisation therapy options due to anatomical or other contraindications to conventional lead-based CRT delivery.

Clinical Validation and Capital Position

EBR partially completed a US$150 million capital raise in 2026, strengthening its balance sheet to support ongoing US commercialisation investment, manufacturing capability expansion, and clinical evidence generation. EBR presented at the J.P. Morgan Healthcare Conference in January 2026 and sponsored a symposium at the Heart Rhythm Society annual meeting in Chicago in April 2026, which management described as standing room only, reflecting the cardiology community's growing interest in wireless endocardial CRT technology.